Drug Trial Radar · NCT07308236
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Dec 31, 2025
Primary completion
Jun 12, 2026
Study completion Jun 12, 2026
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.
Conditions
- Healthy Volunteers
Interventions
E2086Drug
E2086 oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass Balance Recovery of E2086, Expressed as Cumulative Percent of the Radiolabeled DoseTime frame: Day 1 up to Day 21
- Maximum Observed Concentration (Cmax) of [14C]E2086 for Total Radioactivity (TRA) in PlasmaTime frame: Day 1 up to Day 21
- Time to Reach Cmax (Tmax) of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
- Area Under the Concentration-time Curve from Zero Time to Time of Last Quantifiable Concentration [AUC (0-t)] of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
- Area Under the Concentration-time Curve from Zero Time Extrapolated to Infinite Time [AUC (0-inf)] of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
- Terminal Elimination Phase Half-life (t1/2) of [14C]E2086 for TRA in PlasmaTime frame: Day 1 up to Day 21
- Cmax of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
- Tmax of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
- AUC (0-t) of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
- AUC (0-inf) of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
- t1/2 of [14C]E2086 for TRA in Whole BloodTime frame: Day 1 up to Day 21
- Cmax of E2086 and its Metabolite M1 in Plasma Using liquid Chromatography Coupled With Mass Spectrometry (LC-MS/MS)Time frame: Day 1 up to Day 21
- Tmax E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- AUC (0-t) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- AUC (0-inf) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- t1/2 of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- Apparent Total Clearance (CL/F) of E2086 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- Apparent Volume of Distribution (Vz/F) at Terminal Phase of E2086 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- Metabolite Ratio (MRp) of E2086 and its Metabolite M1 in Plasma Using LC-MS/MSTime frame: Day 1 up to Day 21
- Cumulative Amount Excreted in Urine from Zero Time to Time of Last Interval (Ae) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
- Fraction of Dose Excreted in Urine from Zero Time to Time of Last Interval (Fe) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
- Renal Clearance (CLR) of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
- MRu of E2086 and its Metabolite M1 in Urine Using LC-MS/MSTime frame: Day 1 up to Day 21
- Percentage of Administered Radioactive Dose Excreted in Urine, Feces, and Toilet Tissue by TRATime frame: Day 1 up to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.